These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. QC in antisense oligo synthesis. Agris PF; Smith S; Fu C; Simkins SG Nat Biotechnol; 2002 Sep; 20(9):871-2. PubMed ID: 12205500 [No Abstract] [Full Text] [Related]
5. Targeting the Bcl-2 family in cancer therapy. Papadopoulos K Semin Oncol; 2006 Aug; 33(4):449-56. PubMed ID: 16890799 [TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical experience of antisense therapy for solid tumors. Webb MS; Zon G Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760 [TBL] [Abstract][Full Text] [Related]
8. Bcl-2 family members as molecular targets in cancer therapy. Marzo I; Naval J Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457 [TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides as therapeutics for malignant diseases. Ho PT; Parkinson DR Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689 [TBL] [Abstract][Full Text] [Related]
10. Potential roles of antisense technology in cancer chemotherapy. Crooke ST Oncogene; 2000 Dec; 19(56):6651-9. PubMed ID: 11426651 [TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Henry SP; Monteith D; Levin AA Anticancer Drug Des; 1997 Jul; 12(5):395-408. PubMed ID: 9236855 [No Abstract] [Full Text] [Related]
12. Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. McGraw K; McKay R; Miraglia L; Boggs RT; Pribble JP; Muller M; Geiger T; Fabbro D; Dean NM Anticancer Drug Des; 1997 Jul; 12(5):315-26. PubMed ID: 9236849 [No Abstract] [Full Text] [Related]
13. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854 [No Abstract] [Full Text] [Related]
14. Tailoring Ras-pathway--inhibitor combinations for cancer therapy. Blum R; Kloog Y Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760 [TBL] [Abstract][Full Text] [Related]
15. Cancer therapy finds a solid target. Secko D CMAJ; 2005 Aug; 173(3):246. PubMed ID: 16076816 [No Abstract] [Full Text] [Related]
16. How drugs act-23. Drugs and cancer. Smith SE Nurs Times; 1975 Nov; 71(48):1910-1. PubMed ID: 1196972 [No Abstract] [Full Text] [Related]
17. How drugs act--second series. 8. Drugs and cancer. Smith SE Nurs Times; 1967 Mar; 63(9):283-4. PubMed ID: 6018619 [No Abstract] [Full Text] [Related]
18. Advancements of antisense oligonucleotides in treatment of breast cancer. Yang SP; Song ST; Song HF Acta Pharmacol Sin; 2003 Apr; 24(4):289-95. PubMed ID: 12676065 [TBL] [Abstract][Full Text] [Related]